Utilization of a Parental Approach to Informed Consent in Intravenous Tissue Plasminogen Activator Administration Decision-Making: Patient Preference and Ethical Considerations
Table 1
Survey text.
Scenario 1—General approach: “IV-TPA is an FDA-approved clot busting medication. Overall, your mother is more likely to benefit from this medication than be harmed from this medication. We would recommend you allowing us to give this medication to your mother”
Scenario 2—Technical approach: “IV-TPA is an FDA approved clot busting medication. Your mom has a 33% chance of improving from this medication and a 6% chance of harming her with this medication. If you took 100 people and gave them this medication 33 of them would get better, 60 of them wouldn’t get better, but they wouldn’t get worse, 6 of them would get worse but only minorly so, and 1 of them would potentially have a life-threatening complication. Overall, we feel as though your mom is more likely to benefit from this medication than be harmed, and we would recommend you allowing us to give your mom this medication”
Scenario 3—Parental approach: “IV-TPA is an FDA approved clot busting medication. Our team has given this medication to thousands of people over the years and our institution does an amazing job at keeping our patients safe when we give this medication, minimizing any potential harm it could cause. This is a clot busting medication, so the major risk is bleeding, but we feel as though the potential benefit significantly outweighs the minimal risk. I would recommend you letting us give this medication to your mother. I know this is an extremely hard position to be in, but if I was in your shoes, I would want to give this medication to my loved one”
